MO22225 Octavia

• Research type

  Research Study

• Full title

  A Single-arm Phase ll clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.

• IRAS ID

  17355

• Sponsor organisation

  F.Hoffman La- Roche Ltd

• Eudract number

  2008-008336-85

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This study is aiming to measure progression free survival in patients with cancer of the ovaries using a standard treatment of carboplatin plus weekly paclitaxel and bevacizumab (Avastin ©). The patients will be newly diagnosed high risk early stage or advanced stage epithelial ovarian cancer to see if there is an increase in the overall progression free survival once the patients have had the treatment. The study is now closed.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  09/H0801/54

• Date of REC Opinion

  7 Jul 2009

• REC opinion

  Further Information Favourable Opinion